Gain Therapeutics Inc
Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the … Read more
Gain Therapeutics Inc (GANX) - Total Liabilities
Latest total liabilities as of September 2025: $5.06 Million USD
Based on the latest financial reports, Gain Therapeutics Inc (GANX) has total liabilities worth $5.06 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Gain Therapeutics Inc - Total Liabilities Trend (2018–2024)
This chart illustrates how Gain Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Gain Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Gain Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Sirca Paints India Limited
NSE:SIRCA
|
India | ₹1.17 Billion |
|
Ramsdens Holdings PLC
PINK:RSDEF
|
USA | $22.58 Million |
|
CM.com NV
AS:CMCOM
|
Netherlands | €185.12 Million |
|
Audio Pixels Holdings Limited
OTCGREY:ADPXF
|
USA | $19.19 Million |
|
Marco Polo Marine Ltd.
PINK:MRPMF
|
USA | $85.02 Million |
|
VirnetX Holding Corp Common Stock
NYSE:VHC
|
USA | $8.65 Million |
|
Renergen Limited
PINK:RGNTF
|
USA | $1.23 Billion |
|
Hanshin Const
KO:004960
|
Korea | ₩1.45 Trillion |
Liability Composition Analysis (2018–2024)
This chart breaks down Gain Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.52 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.86 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.46 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Gain Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Gain Therapeutics Inc (2018–2024)
The table below shows the annual total liabilities of Gain Therapeutics Inc from 2018 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $4.78 Million | -20.67% |
| 2023-12-31 | $6.03 Million | +15.54% |
| 2022-12-31 | $5.22 Million | +25.25% |
| 2021-12-31 | $4.17 Million | +22.49% |
| 2020-12-31 | $3.40 Million | +206.48% |
| 2019-12-31 | $1.11 Million | -37.01% |
| 2018-12-31 | $1.76 Million | -- |